Kelun-Biotech to Present at J.P. Morgan Conference Amid Global Pharma Shift
Event summary
- Kelun-Biotech (6990.HK) is attending the 44th J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.
- CEO Michael Ge will present on January 15, 2026, at 9:30 AM PST.
- Kelun-Biotech has 30+ ongoing drug projects, 4 approved, 1 in NDA stage, and over 10 in clinical trials.
- The company has proprietary ADC and novel DC platforms, OptiDC™, with 2 approved ADC products.
The big picture
Kelun-Biotech's participation in J.P. Morgan Healthcare Conference highlights the increasing globalization of Chinese biopharmaceutical companies and their ambition to compete on the world stage. The company's focus on ADC and novel DC platforms positions it within a rapidly expanding market segment, but its success hinges on securing international collaborations and navigating complex regulatory hurdles.
What we're watching
- Partnership Strategy
- Kelun-Biotech’s stated pursuit of international partnerships will be scrutinized for the type and scale of deals secured, indicating the company’s appetite for risk and potential impact on its financial performance.
- OptiDC™ Progress
- The advancement of Kelun-Biotech’s OptiDC™ platform beyond the two approved ADC products will be a key indicator of its long-term competitive advantage in the crowded oncology space.
- China Regulatory Landscape
- The speed with which Kelun-Biotech can navigate China’s evolving regulatory environment will influence the timeline for its NDA submission and subsequent commercialization of its pipeline drugs.
Related topics